Clinical Trial Update: A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa [Phase 3]

View source ↗

Summary

Phase III randomized trial of ropinirole prolonged-release as adjunctive therapy in Parkinson's disease patients not optimally controlled on L-Dopa; completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ropinirole prolonged-release (Ropinirole PR) (ropinirole)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-08-07